18th Nov 2019 11:57
(Alliance News) - PureTech Health PLC on Thursday said its affiliate Karuna Therapeutics Inc reported results from the second phase of clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia.
The clinical stage biotechnology company said KarXT demonstrated a statistically significant and clinically meaningful 11.6 point mean reduction in total positive and negative syndrome scale score, compared to placebo.
The trial also showed "good" overall tolerability, PureTech said, and a statistically significant reduction in the secondary endpoints.
"These impressive results are another important validation of PureTech's innovation engine that has generated highly differentiated platforms to address serious diseases, leading to 24 product candidates, including 14 clinical stage and one recently Food & Drug Administration cleared product," said Founder & Chief Executive Daphne Zohar.
"KarXT is now being advanced by one of the leading CNS drug development teams and has the potential to be the first novel therapeutic approach in decades to treat psychosis in patients with schizophrenia and Alzheimer's disease," added Zohar.
PureTech Health shares were trading 1.4% lower in London on Monday at midday at 216.00 pence each.
By Evelina Grecenko; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.
Related Shares:
PureTech